Update on hepatitis C: Direct-acting antivirals
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (28)
- https://doi.org/10.4254/wjh.v7.i28.2829
Abstract
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.Keywords
This publication has 40 references indexed in Scilit:
- Directly acting antivirals against hepatitis C virusJournal of Antimicrobial Chemotherapy, 2011
- Vaccination for hepatitis C virus: closing in on an evasive targetExpert Review of Vaccines, 2011
- A Dynamic View of Hepatitis C Virus Replication ComplexesJournal of Virology, 2008
- Studying Hepatitis C Virus: Making the Best of a Bad VirusJournal of Virology, 2007
- The Hepatitis C Virus Life Cycle as a Target for New Antiviral TherapiesGastroenterology, 2007
- Replication of hepatitis C virusNature Reviews Microbiology, 2007
- Hepatitis C Virus NS5A Protein–A Master Regulator?Gastroenterology, 2006
- Efficient Initiation of HCV RNA Replication in Cell CultureScience, 2000
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989